Clinical Trials Directory
This is a biosample collection study for people in the Surgical Critical Initiative Tissue and Data Acquisition Study If you join this study, you will: - Have blood drawn (an extra 2 teaspoons) at time of your injury or surgery, on Days 1, 3 and 7 after your injury or surgery, and weekly while you are in the hospital. We may also collect fluid or tissue from your wound and pictures of it We will also collect blood near time of surgery or if you get worse. We will also ask to use data collected under TDAP for analyses.
We are doing this to see the effects of giving long-term red blood cell exchange transfusion to patients with sickle cell disease (SCD). We want to know if exchange blood transfusion may help with serious complications of SCD or reduce the chances of a new, serious problem happening.
We are doing this study to find the most effective, safe dose of an experimental drug called SGR-1505 (the study drug). We want to know how well this study drug specifically targets a protein related to your B-cell cancer.
We are doing this study to determine whether specialty palliative care or primary palliative care is the best way to improve the quality of life and experience of patients and their caregivers.
We are doing this study to find out if an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution (the study drug) is a safe and effective option for the treatment of neurotrophic keratopathy.
We are doing this study to find out if a study drug called ivosidenib is a safe and effective option for locally advanced or metastatic conventional chondrosarcoma with an isocitrate dehydrogenase 1 (IDH1) mutation.
We are doing to study to help us design a questionnaire about sexual function specific to women who have mullerian anomalies. We hope this questionnaire can help us improve screening for and treatment of sexual concerns related to mullerian anomalies.
We are doing this study to find out if an experimental drug called patidegib (the study drug) is a safe and effective option for people diagnosed with Gorlin syndrome. We want to know if it can help lower the number of basal cell carcinomas on the face.